BiomX Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by BiomX Inc. on November 17, 2025. The filing reports a material modification to the rights of security holders regarding a reverse stock split of the Company's Common Stock.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and capital structure adjustments.
Material Changes
- Reverse Stock Split Approval: The Board of Directors approved a one-for-nineteen (1:19) reverse stock split on November 13, 2025, following shareholder authorization at the annual meeting on October 16, 2025.
- Effective Date: The split is scheduled to become effective at 12:01 a.m. Eastern Time on November 25, 2025.
- Trading Adjustments: Common Stock is expected to begin trading on the NYSE American on a split-adjusted basis on November 25, 2025, under the new CUSIP number 09090D 509.
- Fractional Shares: No fractional shares will be issued; holders entitled to fractions will receive a round-up to the next whole share.
- Equity Adjustments: Outstanding equity awards, warrants, and convertible preferred stock will be proportionally adjusted. Exercise or conversion prices will be multiplied by 19, and share counts will be divided by 19.
Guidance, Outlook, and Risks
The filing includes a "Safe Harbor" statement regarding forward-looking statements, noting that the effective date and trading commencement are based on current management beliefs and are subject to uncertainties. Investors are directed to the "Risk Factors" section of the Company's Annual Report on Form 10-K filed on March 25, 2025, for a detailed discussion of risks.
Investor Verification Checklist
- Confirm the exact effective time of the reverse stock split (12:01 a.m. ET, November 25, 2025).
- Verify the new CUSIP number (09090D 509) for post-split trading.
- Check brokerage account statements on November 25, 2025, to ensure the 1:19 adjustment has been applied correctly.
- Review the impact of the split on the exercise price and share count of any held options, warrants, or convertible securities.
- Confirm that the Company has filed the Certificate of Amendment with the Delaware Secretary of State as planned.